MX2015009142A - Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico. - Google Patents

Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico.

Info

Publication number
MX2015009142A
MX2015009142A MX2015009142A MX2015009142A MX2015009142A MX 2015009142 A MX2015009142 A MX 2015009142A MX 2015009142 A MX2015009142 A MX 2015009142A MX 2015009142 A MX2015009142 A MX 2015009142A MX 2015009142 A MX2015009142 A MX 2015009142A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
factor receptor
fgr3
polypeptide
Prior art date
Application number
MX2015009142A
Other languages
English (en)
Inventor
Elvire Gouze
Original Assignee
Inserm Inst Nat De La Santé Et De La Rech Médicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inserm Inst Nat De La Santé Et De La Rech Médicale filed Critical Inserm Inst Nat De La Santé Et De La Rech Médicale
Publication of MX2015009142A publication Critical patent/MX2015009142A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona al tratamiento o prevención del trastorno de retraso del crecimiento esquelético, en particular una enfermedad esquelética, desarrollado por pacientes que muestran activación incrementada anormal del receptor de factor de crecimiento de fibroblastos 3 (FGFR3), en particular por expresión de un mutante activado prolongado de FGFR3. Más particularmente, la presente invención se relaciona a un FGFR3 soluble para el uso en el tratamiento o prevención de acondroplasia.
MX2015009142A 2013-01-16 2014-01-16 Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico. MX2015009142A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2013/001480 WO2014111744A1 (en) 2013-01-16 2013-01-16 A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
PCT/EP2014/050800 WO2014111467A1 (en) 2013-01-16 2014-01-16 A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders

Publications (1)

Publication Number Publication Date
MX2015009142A true MX2015009142A (es) 2015-11-06

Family

ID=48289519

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015009142A MX2015009142A (es) 2013-01-16 2014-01-16 Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico.
MX2019013857A MX2019013857A (es) 2013-01-16 2015-07-15 Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019013857A MX2019013857A (es) 2013-01-16 2015-07-15 Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico.

Country Status (20)

Country Link
US (5) US20150344855A1 (es)
EP (2) EP3736285A1 (es)
JP (3) JP2016506914A (es)
KR (3) KR20160002681A (es)
CN (1) CN105121464B (es)
AU (2) AU2013373679A1 (es)
CA (2) CA2898415A1 (es)
DK (1) DK2945967T3 (es)
EA (2) EA201591324A1 (es)
ES (1) ES2796743T3 (es)
HK (1) HK1217959A1 (es)
HU (1) HUE049556T2 (es)
IL (2) IL239810A0 (es)
MX (2) MX2015009142A (es)
PE (1) PE20151664A1 (es)
PL (1) PL2945967T3 (es)
PT (1) PT2945967T (es)
SG (2) SG11201505488XA (es)
SI (1) SI2945967T1 (es)
WO (2) WO2014111744A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014111744A1 (en) 2013-01-16 2014-07-24 INSERM (Institut National de la Santé et de la Recherche Médicale) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
PT3242888T (pt) * 2015-01-07 2020-12-28 Pfizer Armadilhas de fgfr3 solúveis para o tratamento de distúrbios do crescimento ósseo
WO2017188696A1 (ko) * 2016-04-25 2017-11-02 장부다 Vr 공간에서 사용자 인터페이스를 제공하는 방법, 디바이스 및 기록매체
MX2018016257A (es) 2016-07-07 2019-11-21 Therachon Sas Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos.
AU2018335837A1 (en) * 2017-09-20 2020-04-23 Centre National Recherche Scientifique Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides
CN108410803B (zh) * 2018-03-28 2019-02-05 湖南源品细胞生物科技有限公司 一种诱导脂肪干细胞成软骨分化的培养方法和培养液
CN110272900B (zh) * 2019-04-19 2024-03-26 中国人民解放军陆军军医大学 用于制备骨骼发育异常猪模型的sgRNA及其应用
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
JP2022184798A (ja) 2021-06-01 2022-12-13 ファイザー・インク ｓＦＧＦＲ３ポリペプチドを生産するための細胞培養方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
AU721773B2 (en) * 1995-06-12 2000-07-13 Yeda Research And Development Co. Ltd. FGF9 as a specific ligand for FGFR3
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
DE60139720D1 (de) 2000-06-28 2009-10-08 Glycofi Inc Verfahren für die Herstellung modifizierter Glykoproteine
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
AU2002235202A1 (en) * 2000-12-18 2002-07-01 Gene Logic, Inc. Treatment of bone disorders by modulation of fgfr3
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
WO2002102973A2 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
JP4252746B2 (ja) * 2001-10-05 2009-04-08 一和 中尾 軟骨無形成症治療剤
BRPI0203172B8 (pt) * 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
JP2003104908A (ja) * 2001-09-28 2003-04-09 Ichikazu Nakao 軟骨無形成症治療剤
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
IL156495A0 (en) * 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
DK1718756T3 (da) 2004-02-24 2012-02-27 Allergan Inc Botulinumtoksinscreeningassays
DE602006010874D1 (de) 2005-07-22 2010-01-14 Five Prime Therapeutics Inc Zusammensetzungen und verfahren zur behandlung von krankheiten mit fgfr-fusionsproteinen
WO2007144893A2 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
EP2083846B1 (en) 2006-09-28 2015-07-15 Hepacore Ltd. N-terminal fgf variants having increased receptor selectivity and uses thereof
AR063975A1 (es) 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
WO2008133873A2 (en) * 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
WO2010002862A2 (en) 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
AU2009279806B2 (en) 2008-08-04 2015-04-30 Five Prime Therapeutics, Inc. FGFR extracellular domain acidic region muteins
AR073770A1 (es) 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
KR101822663B1 (ko) 2009-03-25 2018-01-29 제넨테크, 인크. 항-ｆｇｆｒ３ 항체 및 그의 사용 방법
CN101585866B (zh) * 2009-07-02 2011-10-05 中国人民解放军第三军医大学野战外科研究所 调节fgfr3活性的多肽及其筛选方法和应用
US8445445B2 (en) 2009-09-15 2013-05-21 Five Prime Therapeutics, Inc. Method of promoting hair growth using FGFR4 extracellular domains
EP2498799B1 (en) 2009-11-13 2016-08-17 Five Prime Therapeutics, Inc. Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2
US8685931B2 (en) 2009-12-17 2014-04-01 Five Prime Therapeutics, Inc. Hair growth methods using FGFR3 extracellular domains
RU2012134637A (ru) 2010-01-14 2014-02-20 Йейл Юниверсити Ингибиторы рецепторных тирозинкиназ (rtk) и способы их применения
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
EP2658979B1 (en) * 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
JP6162707B2 (ja) 2011-10-24 2017-07-12 ハロザイム インコーポレイテッド 抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
JP6382194B2 (ja) 2012-07-24 2018-08-29 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 融合タンパク質およびその方法
KR20150037876A (ko) 2012-07-27 2015-04-08 제넨테크, 인크. Fgfr3 관련 상태의 치료 방법
US11230589B2 (en) 2012-11-05 2022-01-25 Foundation Medicine, Inc. Fusion molecules and uses thereof
WO2014111744A1 (en) 2013-01-16 2014-07-24 INSERM (Institut National de la Santé et de la Recherche Médicale) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
CN106662577B (zh) 2014-01-24 2020-07-21 恩格姆生物制药公司 结合蛋白及其使用方法
PT3242888T (pt) 2015-01-07 2020-12-28 Pfizer Armadilhas de fgfr3 solúveis para o tratamento de distúrbios do crescimento ósseo
MX2018016257A (es) 2016-07-07 2019-11-21 Therachon Sas Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos.
AU2018335837A1 (en) 2017-09-20 2020-04-23 Centre National Recherche Scientifique Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides

Also Published As

Publication number Publication date
JP2016506912A (ja) 2016-03-07
AU2014206844A1 (en) 2015-07-16
US10724014B2 (en) 2020-07-28
JP2016506914A (ja) 2016-03-07
EP2945967A1 (en) 2015-11-25
US20210032607A1 (en) 2021-02-04
MX2019013857A (es) 2020-01-20
US20150353624A1 (en) 2015-12-10
JP6995069B2 (ja) 2022-02-04
WO2014111744A1 (en) 2014-07-24
PL2945967T3 (pl) 2020-11-16
US20150344855A1 (en) 2015-12-03
KR20210054026A (ko) 2021-05-12
HUE049556T2 (hu) 2020-09-28
EA201591324A1 (ru) 2016-01-29
CA2896978A1 (en) 2014-07-24
PT2945967T (pt) 2020-05-28
WO2014111467A1 (en) 2014-07-24
PE20151664A1 (es) 2015-11-28
SI2945967T1 (sl) 2020-10-30
IL239996A0 (en) 2015-08-31
US20210032608A1 (en) 2021-02-04
US20200199545A1 (en) 2020-06-25
KR102249454B1 (ko) 2021-05-07
SG11201505488XA (en) 2015-08-28
EP2945967B1 (en) 2020-04-15
CN105121464B (zh) 2021-05-07
IL239810A0 (en) 2015-08-31
AU2013373679A1 (en) 2015-08-13
CA2898415A1 (en) 2014-07-24
HK1217959A1 (zh) 2017-01-27
KR20150122136A (ko) 2015-10-30
EA201591055A1 (ru) 2016-04-29
JP2019107006A (ja) 2019-07-04
ES2796743T3 (es) 2020-11-30
CN105121464A (zh) 2015-12-02
SG11201505140XA (en) 2015-07-30
US11814654B2 (en) 2023-11-14
EP3736285A1 (en) 2020-11-11
US11702642B2 (en) 2023-07-18
DK2945967T3 (da) 2020-07-13
KR20160002681A (ko) 2016-01-08

Similar Documents

Publication Publication Date Title
MX2019013857A (es) Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico.
ZA202202711B (en) Sustained-release dosage forms of ruxolitinib
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2021011939A (es) Compuestos neuroactivos y metodos de uso de los mismos.
JO3343B1 (ar) أحماض 5- أمينوتتراهيدروكوينولين-2- كربوكسيليك جديدة واستخدامها
MX2019010322A (es) Composiciones farmaceuticas para el tratamiento combinado.
PH12015501596A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
PH12014502537A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins
MX2019008917A (es) Composiciones farmaceuticas para terapia de combinacion.
NZ713080A (en) Pyridin-4-yl derivatives
MX364528B (es) Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas.
AU2014352875A8 (en) Gastrin antagonists (eg YF476, netazepide) for treatment and prevention of osteoporosis
PH12017501918A1 (en) Multi-peptide composition
SG10201809418VA (en) New administration routes of insulin, insulin analogs or derivatives of insulin
EA201491939A1 (ru) Модуляторы прогестероновых рецепторов для применения в профилактике или лечении болезней, опосредованных андрогенами
PH12019501070A1 (en) Sustained-release dosage forms of ruxolitinib
JO3621B1 (ar) مركبات وتركيبات على هيئة عوامل مساعدة لمستقبل 7 يشبه toll
GEP201706747B (en) Pharmaceutical composition for reducing the trimethylamine n-oxide level

Legal Events

Date Code Title Description
FG Grant or registration